Tags

Type your tag names separated by a space and hit enter

Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Future Med Chem. 2016; 8(2):211-26.FM

Abstract

In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes - the ruthenium(II/III)-dithiocarbamates - which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines.

Authors+Show Affiliations

Department of Chemical Sciences, University of Padova, Via Marzolo 1, Padova, 35131, Italy.Department of Chemical Sciences, University of Padova, Via Marzolo 1, Padova, 35131, Italy.Department of Chemical Sciences, University of Padova, Via Marzolo 1, Padova, 35131, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26807601

Citation

Nardon, Chiara, et al. "Is Matching Ruthenium With Dithiocarbamato Ligands a Potent Chemotherapeutic Weapon in Oncology?" Future Medicinal Chemistry, vol. 8, no. 2, 2016, pp. 211-26.
Nardon C, Brustolin L, Fregona D. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology? Future Med Chem. 2016;8(2):211-26.
Nardon, C., Brustolin, L., & Fregona, D. (2016). Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology? Future Medicinal Chemistry, 8(2), 211-26. https://doi.org/10.4155/fmc.15.175
Nardon C, Brustolin L, Fregona D. Is Matching Ruthenium With Dithiocarbamato Ligands a Potent Chemotherapeutic Weapon in Oncology. Future Med Chem. 2016;8(2):211-26. PubMed PMID: 26807601.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology? AU - Nardon,Chiara, AU - Brustolin,Leonardo, AU - Fregona,Dolores, Y1 - 2016/01/25/ PY - 2016/1/26/entrez PY - 2016/1/26/pubmed PY - 2016/9/22/medline KW - NAMI-A KW - cancer KW - chemoprotectant KW - cisplatin KW - dithiocarbamate KW - heteroleptic KW - homoleptic KW - metal complexes KW - redox reaction KW - ruthenium SP - 211 EP - 26 JF - Future medicinal chemistry JO - Future Med Chem VL - 8 IS - 2 N2 - In the last years, several metal-based compounds have been designed and biologically investigated worldwide in order to obtain chemotherapeutics with a better toxicological profile and comparable or higher antiblastic activity than the clinically-established platinum-based drugs. In this context, researchers have addressed their attention to alternative nonplatinum derivatives able to maximize the anticancer activity of the new drugs and to minimize the side effects. Among them, a number of ruthenium complexes have been developed, including the compounds NAMI-A and KP1019, now in clinical trials. Here, we report the results collected so far for a particular class of ruthenium complexes - the ruthenium(II/III)-dithiocarbamates - which proved more potent than cisplatin in vitro, even at nanomolar concentrations, against a wide panel of human tumor cell lines. SN - 1756-8927 UR - https://www.unboundmedicine.com/medline/citation/26807601/Is_matching_ruthenium_with_dithiocarbamato_ligands_a_potent_chemotherapeutic_weapon_in_oncology L2 - https://www.future-science.com/doi/full/10.4155/fmc.15.175?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -